June 11, 2019
Congratulations to Dr. Katalin Susztak for being a keynote speaker at the nnual Meeting of the European Renal Association-European Dialysis and Transplantation (ERA-EDTA) meeting.
May 21, 2019
SR9009 is a compound that can lead to a wide range of health benefits in animals, including reduced risk of obesity and type 2 diabetes. Until now, researchers – and companies that sell the compound for human use in the form of a nutraceutical – have attributed the effects to SR9009’s role in altering the body’s circadian clock, specifically its work through proteins called REV-ERBS that link metabolism and circadian rhythm. However, in a first-of-its-kind study from Penn Medicine, published today in PNAS, researchers found that SR9009 can effect cell growth and metabolic function without the involvement of REV-ERBs.
Learn More - Penn Medicine Press Release